A 48-week, global, randomized, placebo-controlled Phase 3 trial in myotonic dystrophy type 1 will enroll approximately 150 participants aged 16 and older, randomized 1:1 to zeleciment basivarsen 6.8 mg/kg IV every eight weeks or placebo. The primary endpoint is change from baseline in the five times sit to stand test at week 49, with secondary measures that include video hand opening time, quantitative muscle testing, the 10-Meter Walk/Run, the Myotonic Dystrophy Health Index, and additional patient- and clinician-reported outcomes. Exploratory endpoints target central nervous system domains, and a 24-week open-label extension follows the double-blind period.
Dyne Therapeutics has initiated the Phase 3 HARMONIA trial and opened the first sites for enrollment, with FDA-aligned design and protocol. The study is positioned as the confirmatory trial intended to support conversion of a potential U.S. Accelerated Approval—sought from the ongoing Phase 1/2 ACHIEVE expansion using myotonia measured by video hand opening time—into traditional approval. The company plans to leverage HARMONIA to support ex-U.S. marketing applications as well.
Strategically, this is a two-step regulatory plan that anchors early authorization on an intermediate, disease-relevant signal while reserving a longer, functionally grounded endpoint to secure full approval. Selecting five times sit to stand as the primary endpoint places a clear bet on a pragmatic, clinic-friendly functional assessment that maps to daily activities and lower-extremity weakness—areas of high unmet need in DM1—and seeks to demonstrate multi-system benefit beyond myotonia. The regimen’s Q8W intravenous dosing strikes a balance between operational feasibility and sustained exposure for a large-molecule conjugate designed to reach both muscle and CNS via transferrin receptor targeting, aiming to differentiate on breadth of effect rather than isolated biomarkers.
For sites, the design raises immediate executional considerations. Standardizing performance-based measures like five times sit to stand across geographies will require tight rater training, adherence to timing procedures, and mitigation of learning effects to control variability. The incorporation of video-based assessments and multiple PROs/ClinROs implies centralized quality control workflows, robust ePRO infrastructure, and reliable audiovisual capture. Infusion capacity on an every-eight-week cadence must be coordinated alongside visit schedules that accommodate the multi-domain assessment battery. Adolescent inclusion expands eligible pools but adds consent and coordination complexity.
For sponsors and CROs, the endpoint mix diversifies regulatory risk but complicates data operations. Harmonizing performance outcomes, digital/video assessments, and CNS exploratory readouts will test statistical planning and data cleaning at scale. Enrollment velocity in a rare, functionally heterogeneous population is a gating factor; screen failure rates may hinge on baseline mobility thresholds and comorbidity exclusions. The FDA alignment on endpoint selection could set a template for future DM1 programs, but ex-U.S. acceptance of five times sit to stand as pivotal evidence remains to be demonstrated.
The next phase hinges on two timelines converging: whether the ACHIEVE expansion delivers a sufficiently persuasive myotonia signal to justify an Accelerated Approval filing, and whether HARMONIA can enroll on schedule and maintain assay fidelity to read out a durable functional benefit at 49 weeks. Key risks include placebo response and site-to-site variability on five times sit to stand, the definition and reproducibility of a clinically meaningful change, and safety tolerability of a transferrin receptor–targeted ASO conjugate over repeated dosing. Watch for early enrollment disclosures, protocol amendments related to endpoint execution, interim safety updates, and regulatory commentary on the validity of video hand opening time as an intermediate endpoint. If both tracks hold, the program could crystallize a functional-evidence standard in DM1; if not, misalignment between intermediate and confirmatory outcomes could extend timelines and reopen the endpoint debate.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
